Research for HYBIO Pharmaceutical's first domestic marketing application for its tirzepatide injection has been accepted, and the dual filing in China and the US is accelerating its global commercial layout. - aVenture Research
Hybio Pharmaceutical
HYBIO Pharmaceutical's first domestic marketing application for its tirzepatide injection has been accepted, and the dual filing in China and the US is accelerating its global commercial layout.
Recently, HYBIO Pharmaceutical Co., Ltd. (hereinafter referred to as “HYBIO Pharmaceutical”)’s self-developed application for the registration and marketing authorization of Tirzepatide injection, a domestically produced pharmaceutical product, was officially accepted by the National Medical Products Administration (NMPA). HYBIO Pharmaceutical has become the first company in China to submit an application for Tirzepatide injection, marking an important milestone in the process of localizing and